PIK3CA and adenocarcinoma: Patients with metastatic or recurrent adenocarcinomas who carried PIK3CA mutations (n = 3) achieved a median OS of 19.4 months (95% CI, 0 – 43.6), similar to those who did not carry PIK3CA mutations (n = 19; 14.2 months, 95% CI, 4.0–24.4; p = 0.75), as shown in Figure 4B.